NIT
MCRB icon

NumerixS Investment Technologies’s Seres Therapeutics MCRB Stock Holding History

NumerixS Investment Technologies’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-435
Closed -$107K – 1251
2016
Q3 		$107K Buy
435
+95
+28% +$33.3K 0.01% 818
2016
Q2 		$198K Buy
+340
New +$199K 0.03% 706

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NumerixS Investment Technologies's MCRB Position: Q4 2016 in Review

NumerixS Investment Technologies sold out of Seres Therapeutics (MCRB) in Q4 2016, closing a stake of 435 shares — an estimated $107K sold.

NumerixS Investment Technologies first reported a position in MCRB in Q2 2016 and held it in 2 quarters. The position peaked at $198K in Q2 2016. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

  • NumerixS Investment Technologies reported no remaining Seres Therapeutics position as of Q4 2016 after selling out during the quarter.
  • NumerixS Investment Technologies sold 435 Seres Therapeutics shares in Q4 2016, an estimated $107K.
  • NumerixS Investment Technologies first reported a position in Seres Therapeutics in Q2 2016 and held it in 2 quarters.
  • NumerixS Investment Technologies's Seres Therapeutics position peaked at $198K in Q2 2016.
  • 89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on NumerixS Investment Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.